Clinical features | Anti-AQP4 (+) n = 14 | Anti-AQP4 (-) n = 17 | Total n = 31 | P value |
---|---|---|---|---|
Female/male ratio | 1:13 | 4:13 | 5:26 | 0.344 |
Age of onset (±SD) (years) | 31.21 ± 8.81 | 30.82 ± 8.55 | 31.00 ± 8.52 | 0.902 |
Duration of follow-up (months) | 46.35 ± 13.80 | 40.00 ± 11.30 | 44.51 ± 14.86 | 0.169 |
Number of episodes | 3.71 ± 0.73 | 2.41 ± 1.54 | 3.00 ± 1.39 | 0.005 |
Annual relapse rate | 1.05 ± 0.40 | 0.72 ± 0.40 | 0.87 ± 0.43 | 0.031 |
NMOSD | 14/14 (100Â %) | 3/17 (17.65Â %) | 17/31 (54.84Â %) | <0.001 |
NMO | 10/14 (71.43Â %) | 2/17 (11.76Â %) | 12/31 (38.71Â %) | 0.001 |
MS | 0/14 (0.00Â %) | 7/17 (41.17Â %) | 7/31 (22.58Â %) | 0.007 |
Monophasic | 0/14 (0.00Â %) | 7/17 (41.17Â %) | 7/31 (22.58Â %) | 0.007 |
CSF examinations | ||||
 Total protein (mg/dl, ±SD) | 0.30 ± 0.10 | 0.25 ± 0.12 | 0.27 ± 0.11 | 0.204 |
 Cell counts (number/μl, ±SD) | 11.29 ± 4.27 | 8.47 ± 2.07 | 9.74 ± 2.21 | 0.07 |
 Pleocytosis >50WBC/μl (%) | 2/14 | 0/17 | 2/31 | 0.196 |
 IgG index | 0.68 ± 0.07 | 0.42 ± 0.13 | 0.54 ± 0.17 | <0.01 |
 Oligoclonal bands | 1/14 (7.14 %) | 1/17 (5.88 %) | 2/31 (6.45 %) | 0.708 |
EDSS a | 3 (2–4) | 3 (2–3) | 3 (2–4) | 0.141 |
EDSS b | 5 (3–7) | 2.5 (1.5–4.5) | 3.5 (1.5–7) | <0.001 |